A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

Gunter von Minckwitz; Bettina Conrad; Toralf Reimer; Thomas Decker; Holger Eidtmann; Wolfgang Eiermann; John Hackmann; Volker Möbus; Frederik Marmé; Jochem Potenberg; Elmar Stickeler; Eike Simon; Christoph Thomssen; Jens Huober; Carsten Denkert; Joachim Alfer; Christian Jackisch; Valentina Nekljudova; Nicole Burchardi; Sibylle Loibl;

doi:10.1002/cncr.29506

A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

Cancer ◽

10.1002/cncr.29506 ◽

2015 ◽

Vol 121 (20) ◽

pp. 3639-3648 ◽

Cited By ~ 31

Author(s):

Gunter von Minckwitz ◽

Bettina Conrad ◽

Toralf Reimer ◽

Thomas Decker ◽

Holger Eidtmann ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Elderly Patients ◽

Early Breast Cancer ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2006.12.007 ◽

2007 ◽

Vol 64 (1) ◽

pp. 64-72 ◽

Cited By ~ 28

Author(s):

G. Romieu ◽

M. Clemens ◽

R. Mahlberg ◽

P. Fargeot ◽

M. Constenla ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Elderly Patients ◽

Phase 2 ◽

Phase 2 Trial ◽

High Risk Breast Cancer ◽

High Risk Breast ◽

Risk Breast Cancer ◽

Randomized Phase 2

Download Full-text

Abstract PD3-01: Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

10.1158/1538-7445.sabcs18-pd3-01 ◽

2019 ◽

Cited By ~ 14

Author(s):

LA Emens ◽

F Esteva ◽

M Beresford ◽

C Saura ◽

M De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Phase 2 ◽

Phase 2 Study ◽

Previously Treated ◽

Randomized Phase 2

Download Full-text

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Cited By ~ 3

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Randomized Phase 2

Download Full-text

Persistence of circulating tumor cells in high risk early breast cancer patients five years after adjuvant chemotherapy and late recurrence: Results from the adjuvant SUCCESS A trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.515 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 515-515 ◽

Cited By ~ 6

Author(s):

Wolfgang Janni ◽

Brigitte Kathrin Rack ◽

Peter A. Fasching ◽

Lothar Haeberle ◽

Hans Tesch ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Early Breast Cancer ◽

Late Recurrence ◽

Breast Cancer Patients

Download Full-text

Trasutuzumab versus observation for high-risk, non-metastatic, HER2 non-amplified breast cancer with Circulating Tumor Cells (EORTC 90091-10093 Treat CTC): A European, multicenter, randomized phase 2 trial

European Journal of Cancer ◽

10.1016/s0959-8049(18)30263-6 ◽

2018 ◽

Vol 92 ◽

pp. S7

Author(s):

M. Ignatiadis ◽

S. Litiere ◽

F. Rothe ◽

S. Riethdorf ◽

C. Proudhon ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

A risk-benefit assessment approach to selection of adjuvant chemotherapy in elderly patients with early breast cancer: A mini review

Indian Journal of Medical and Paediatric Oncology ◽

10.4103/ijmpo.ijmpo_96_17 ◽

2017 ◽

Vol 38 (4) ◽

pp. 526 ◽

Cited By ~ 4

Author(s):

Sudeep Gupta ◽

Vivek Agarwala ◽

Neha Choudhary

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Elderly Patients ◽

Early Breast Cancer ◽

Benefit Assessment ◽

Risk Benefit Assessment ◽

Assessment Approach ◽

Selection Of

Download Full-text

Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Acta Oncologica ◽

10.1080/0284186x.2020.1851045 ◽

2020 ◽

pp. 1-8

Author(s):

Anne Sofie Brems-Eskildsen ◽

Søren Linnet ◽

Hella Danø ◽

Adam Luczak ◽

Peter Michael Vestlev ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Oral Capecitabine ◽

Phase 2 Study ◽

Metronomic Treatment ◽

Randomized Phase 2

Download Full-text

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05755-7 ◽

2020 ◽

Vol 183 (2) ◽

pp. 419-428 ◽

Cited By ~ 1

Author(s):

Richard S. Finn ◽

Katalin Boer ◽

Igor Bondarenko ◽

Ravindranath Patel ◽

Tamas Pinter ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Adjuvant chemotherapy in elderly patients with triple-negative early breast cancer: A french experience from a single institution

Journal of Geriatric Oncology ◽

10.1016/j.jgo.2013.09.014 ◽

2013 ◽

Vol 4 ◽

pp. S28-S29

Author(s):

J. Leblanc ◽

P. Barthelemy ◽

M.-P. Wissler ◽

D. Heitz ◽

C. Mathelin ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Elderly Patients ◽

Early Breast Cancer ◽

Triple Negative ◽

Single Institution ◽

French Experience

Download Full-text

P4-16-05: A Randomized Phase 2 Study of a Loading Dose of Ibandronate in Patients with Bone Metastases from Breast Cancer.

10.1158/0008-5472.sabcs11-p4-16-05 ◽

2011 ◽

Author(s):

DM Ritchie ◽

C Bray ◽

P Canney

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Loading Dose ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text